Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

hich may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Disclosure Notice

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2009, and statements regarding our clinical development programs, the effectiveness of our Vancocin and Cinryze sales efforts, our estimates of future tax rates, or our ability to execute a successful launch of Cinryze, our ability to conduct future studies with maribavir, and the timing and potential outcomes of the review of our regulatory submission related to an acute treatment indication for Cinryze.

Our 2009 revenue guidance is based upon our plans to remain vigorous in our opposition to any bioequivalence approach considered for use in approving generic formulations of Vancocin that does not require rigorous scientific methods to demonstrate safety and efficacy consistent with good medicine and science. There can be no assurance that the FDA will agree with the positions stated in our Vancocin related submissions or that our efforts to oppose the FDA's December 2008 bioequivalence guidance for Vancocin will be successful. We cannot predict the timeframe in which the FDA will make a decision regarding either our citizen petition for Vancocin or the approval of generic versions of Vancocin. If we are unable to change the recommendation set forth by the FDA in December 2008, the threat of generic competition will be high. The entry of competing generic products will significantly affect our sales of Vancoci
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange (WEDI), ... health IT to create efficiencies in healthcare information exchange, ... has developed an issue brief titled, “What is ... HPID Workgroup, a part of WEDI’s Strategic National HPID ... and Medicaid Services (CMS) to identify common misuse of ...
(Date:7/28/2014)... 28, 2014 Proove Biosciences , ... be exhibiting data and research conducted through their latest ... Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. The ... Hyatt Regency, in Orlando, Florida. , The ... competence of physicians who care for patients suffering specificity ...
(Date:7/28/2014)... According to the ... Instruments, Services), Methods (Phenotypic, Genotypic), Applications (Pharmaceutical, Diagnostic, Environmental, ... - Global Forecasts to 2019" published by ... at $896.5 Million in 2014 and is ... growing at a CAGR of 5.9% from ...
(Date:7/28/2014)... , July 28, 2014   Propeller Health , ... announced the hire of Brad Towle as ... be responsible for driving the company,s sales growth, customer ... in healthcare, and specifically his past role in the ... the company at this pivotal time in the industry," ...
Breaking Biology Technology:WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2
... 13 Joseph F. Finn, Jr.,C.P.A. ("Finn"), Assignee of ... creditors, announced today that all pharmaceutical,intellectual property will be ... One of the pieces of intellectual property for ... a branded drug that currently has,more than $2 billion ...
... new research from,BioInformatics, LLC ( http://www.gene2drug.com ) -- ... life science industry -- service,providers in the life ... to,demonstrate customer value. As offerings become more diverse, ... of all three, vendors must respond to customers, ...
... the,appointment of David A. Mann to the Company,s Board ... Board,s audit committee., "Dave,s years of executive management ... an invaluable asset to Omeros,",stated Gregory Demopulos, M.D., Chairman ... our Board, and I expect that he will play ...
Cached Biology Technology:BioInformatics, LLC Offers Solutions for Optimizing Service and/or Maintenance Contracts 2BioInformatics, LLC Offers Solutions for Optimizing Service and/or Maintenance Contracts 3Omeros Appoints David A. Mann to its Board of Directors 2
(Date:7/29/2014)... has received from the National Institutes of Health ... project to support the further development of 23andMe,s ... , Specifically, the grant supports four areas ... to improve the company,s ability to identify novel ... to support the collection of a broader set ...
(Date:7/29/2014)... latest research from the University of Adelaide ... of many preterm children can perform almost as well as ... University,s Robinson Research Institute has found that as ... early life, their cognitive abilities as a teenager can potentially ... results of the study, published in this month,s issue of ...
(Date:7/29/2014)... in 100,000 people characterized by a loss of nerve ... a new study by a team of researchers at KU ... other European institutions confirms for the first time that achalasia ... in Nature Genetics , is an important step towards ... in the lower esophagus opens, allowing food to enter the ...
Breaking Biology News(10 mins):23andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 3Preterm children's brains can catch up years later 2Mysterious esophagus disease is autoimmune after all 2
... 14, 2011 -- The University of Miami Rosenstiel School of ... Peter Mumby is the 2011 recipient of The Rosenstiel Award, ... ecologist and professor at Australia,s University of Queensland, is the ... understand the benefits and limitations of conservation strategies for coral ...
... Ryou, researcher at the UK Sanders-Brown Center on ... genetics in the UK College of Medicine, may ... Prion diseases, which include Creutzfeldt-Jakob disease in ... in cattle, are caused by prions unconventional ...
... COLUMBIA, Mo. Plants harvest energy through the process of ... about the genes that regulate the transport of sugars to ... Missouri researcher has received a $6.6 million grant from the ... the genes that control the movement of carbohydrates in corn. ...
Cached Biology News:Peter Mumby to receive prestigious 2011 Rosenstiel Award from the University of Miami 2MU researcher leads new $6.6 million study that could lead to better corn plants 2
... Phosphatase 2 (LPP2) fractionated ... solution Solution in ... 0.08% sodium azide. unique ... human LPP2 protein. The ...
Rabbit polyclonal to Retinoic Acid Receptor beta 2 ( Abpromise for all tested applications). entrezGeneID: 5915...
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
...
Biology Products: